Avulux and BluTech announced a direct partnership under which BluTech will manufacture the next generation of Avulux migraine and light sensitivity lenses. These lenses fully replaced the current generation of Avulux lenses starting on Jan. 5, 2026, improving lens quality in several important ways while maintaining the unique spectral curve patients and providers trust.
ABOUT THE PARTNERSHIP
After a rigorous research and development process undertaken jointly by both organizations, the next generation of Avulux lenses will leverage BluTech’s unique, proprietary lens composition to greatly improve Abbe value from 29 to 38, resulting in clearer, sharper vision with less color fringing or blur, improved contrast and reduced eye strain.
This new generation of Avulux lenses will also feature improved cosmetic appearance and better color consistency from lens to lens, regardless of geometry, thickness, material or other factors. These lenses will also be significantly more workable by both optical labs and independent eye care providers, with higher heat tolerances that can withstand virtually all lab processes, allowing Avulux lenses to be more compatible with the widest possible range of coatings.
Avulux and BluTech have also begun work on both a polarized and photochromic lens, both of which are anticipated to be available in the second quarter of 2026.
ABOUT BLUTECH AND AVULUX
BluTech launched its first light management lens in 2017, after extensive testing with more than 50 doctor’s offices. Since then, they have established themselves as a trusted partner in providing solutions industry-wide for addressing harmful light.
“BluTech is proud to support eyecare providers through extensive and synergistic partnerships with emerging lens innovations like Avulux,” says Greg Naes, President of BluTech. “Both organizations are committed to supporting the industry with best-in-class solutions, and both organizations have light management products with demonstrable patient impact. This is an exciting partnership.”
The Avulux lens is the only lens that has been clinically proven for people living with migraine and light sensitivity. In a 2020 double blind, randomized, placebo-controlled study conducted by an independent clinical research organization, the Avulux lens achieved both clinical and statistical significance when compared to a clear placebo lens.
“We are thrilled to partner with BluTech on the most significant product improvement in the history of our company,” said Dr. Charles Posternack, Chief Executive Officer, Avulux. “This partnership will give every lab and eyecare provider the opportunity to provide Avulux lenses, ensuring that migraine sufferers everywhere will have access this life-changing technology.”
